Raiffeisen Bank International AG (RCEL)
XWBO 
Summary
RCEL Chart
All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy
Avita Medical (RCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Avita Medical Inc. (RCEL) is a Great Momentum Stock: Should You Buy?
Does Avita Medical Inc. (RCEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
AVITA Medical: Favorable Reimbursements For Skin Wound Care
AVITA Medical's reimbursement is now becoming more predictable. I believe this removes one of their main adoption barriers going forward. The RECELL GO international rollout and PermeaDerm's positive clinical economics also broaden RCEL's long-term potential. Management said they should reach their cash flow breakeven target by Q4 2026, which would further derisk the stock as a whole.
Raiffeisen Bank International AG (RCEL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Raiffeisen Bank International AG ever had a stock split?
Raiffeisen Bank International AG Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Cary G. Vance CEO | XWBO Exchange | US05380C1027 ISIN |
| US Country | 226 Employees | - Last Dividend | 30 Jun 2020 Last Split | - IPO Date |
Overview
AVITA Medical Inc. is a pioneering commercial-stage regenerative tissue company with operations extending across the United States, Australia, and the United Kingdom. Founded in 2000 and headquartered in Valencia, California, the company specializes in delivering innovative regenerative products aimed at tackling unmet medical needs in various domains, including burn injuries, trauma injuries, chronic wounds, and several dermatological and aesthetic conditions such as vitiligo. Through its patented and proprietary technology, AVITA Medical leverages the regenerative capabilities of a patient's own skin to develop treatments that offer new hope and possibilities in healing. Initially known as AVITA Therapeutics, Inc., the company underwent a name change in December 2020 to better reflect its medical focus and commitment to advancing regenerative medicine.
Products and Services
The cornerstone of AVITA Medical's innovative offerings is the RECELL System, alongside its involvement in promising research collaborations aimed at expanding the potential applications of its regenerative technology:
- RECELL System: This leading-edge device stands out in the field of regenerative medicine by allowing healthcare professionals to produce a suspension of Spray-On Skin cells from a small sample of the patient's own skin. This suspension can then be used in treating acute thermal burns in adult patients aged eighteen years and over. The RECELL System encapsulates the essence of AVITA Medical's mission by harnessing the body's natural healing processes to achieve remarkable recovery outcomes in burn care.
- Research Collaborations: AVITA Medical has entered into vital research collaborations to explore and expand the horizons of regenerative medicine further:
- University of Colorado School of Medicine: This partnership is dedicated to establishing pre-clinical proof-of-concept for a novel spray-on treatment of genetically corrected cells, aiming to push the boundaries of regenerative healing practices.
- Houston Methodist Research Institute: This collaboration seeks to investigate the molecular reversal of cellular aging through a unique cell suspension delivery system, embodying AVITA Medical's commitment to innovation and its potential to revolutionize the field of regenerative medicine.
